Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oscar Mammoliti

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Future Medicinal Chemistry|February 17, 2015
Progress toward JAK1-selective inhibitorsChristel J Menet, Oscar Mammoliti, Miriam López-Ramos
Organic & Biomolecular Chemistry|August 8, 2014
Organophosphorus-catalyzed diaza-Wittig reaction: application to the synthesis of pyridazinesHassen Bel Abed, Oscar Mammoliti, Omprakash Bande, et al.
The Journal of Organic Chemistry|August 17, 2013
Strategy for the synthesis of pyridazine heterocycles and their derivativesHassen Bel Abed, Oscar Mammoliti, Omprakash Bande, et al.
Frontiers in Pharmacology|November 13, 2018
Identification and Characterization of Novel CFTR PotentiatorsMaarten Gees, Sara Musch, Steven Van der Plas, et al.
Journal of Medicinal Chemistry|January 5, 2021
Discovery of GLPG2451, a Novel Once Daily Potentiator for the Treatment of Cystic FibrosisSteven E Van der Plas, Hans Kelgtermans, Oscar Mammoliti, et al.
Journal of Medicinal Chemistry|May 28, 2024
Discovery of GLPG3667, a Selective ATP Competitive Tyrosine Kinase 2 Inhibitor for the Treatment of Autoimmune DiseasesOscar Mammoliti, Sébastien Martina, Pieter Claes, et al.
Journal of Medicinal Chemistry|May 3, 2021
Discovery of the S1P2 Antagonist GLPG2938 (1-[2-Ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a Preclinical Candidate for the Treatment of Idiopathic Pulmonary FibrosisOscar Mammoliti, Adeline Palisse, Caroline Joannesse, et al.
Bioorganic & Medicinal Chemistry|October 24, 2024
Design of a potent and selective dual JAK1/TYK2 inhibitorOscar Mammoliti, Christel Menet, Céline Cottereaux, et al.
Journal of Medicinal Chemistry|November 18, 2017
Discovery of N-(3-Carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-lH-pyrazole-5-carboxamide (GLPG1837), a Novel Potentiator Which Can Open Class III Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channels to a High ExtentSteven E Van der Plas, Hans Kelgtermans, Tom De Munck, et al.
Bioorganic & Medicinal Chemistry Letters|August 25, 2025
Discovery of GLPG4471, a potent and selective IRAK4 inhibitor for the treatment of inflammatory and autoimmune diseasesOscar Mammoliti, Florence Bonnaterre, Gregory Newsome, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Future Medicinal Chemistry|February 17, 2015
Progress toward JAK1-selective inhibitorsChristel J Menet, Oscar Mammoliti, Miriam López-Ramos
Organic & Biomolecular Chemistry|August 8, 2014
Organophosphorus-catalyzed diaza-Wittig reaction: application to the synthesis of pyridazinesHassen Bel Abed, Oscar Mammoliti, Omprakash Bande, et al.
The Journal of Organic Chemistry|August 17, 2013
Strategy for the synthesis of pyridazine heterocycles and their derivativesHassen Bel Abed, Oscar Mammoliti, Omprakash Bande, et al.
Frontiers in Pharmacology|November 13, 2018
Identification and Characterization of Novel CFTR PotentiatorsMaarten Gees, Sara Musch, Steven Van der Plas, et al.
Journal of Medicinal Chemistry|January 5, 2021
Discovery of GLPG2451, a Novel Once Daily Potentiator for the Treatment of Cystic FibrosisSteven E Van der Plas, Hans Kelgtermans, Oscar Mammoliti, et al.
Journal of Medicinal Chemistry|May 28, 2024
Discovery of GLPG3667, a Selective ATP Competitive Tyrosine Kinase 2 Inhibitor for the Treatment of Autoimmune DiseasesOscar Mammoliti, Sébastien Martina, Pieter Claes, et al.
Journal of Medicinal Chemistry|May 3, 2021
Discovery of the S1P2 Antagonist GLPG2938 (1-[2-Ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a Preclinical Candidate for the Treatment of Idiopathic Pulmonary FibrosisOscar Mammoliti, Adeline Palisse, Caroline Joannesse, et al.
Bioorganic & Medicinal Chemistry|October 24, 2024
Design of a potent and selective dual JAK1/TYK2 inhibitorOscar Mammoliti, Christel Menet, Céline Cottereaux, et al.
Journal of Medicinal Chemistry|November 18, 2017
Discovery of N-(3-Carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-lH-pyrazole-5-carboxamide (GLPG1837), a Novel Potentiator Which Can Open Class III Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channels to a High ExtentSteven E Van der Plas, Hans Kelgtermans, Tom De Munck, et al.
Bioorganic & Medicinal Chemistry Letters|August 25, 2025
Discovery of GLPG4471, a potent and selective IRAK4 inhibitor for the treatment of inflammatory and autoimmune diseasesOscar Mammoliti, Florence Bonnaterre, Gregory Newsome, et al.
Pageof 2